Rafarma Pharmaceuticals Valuation
| RAFA Stock | USD 0.09 0 4.40% |
Rafarma Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Rafarma Pharmaceuticals from analyzing the company fundamentals such as Price To Earning of (1.29) X, return on equity of -7.0E-4, and Operating Margin of (0.81) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Rafarma Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Rafarma Pharmaceuticals is based on 3 months time horizon. Increasing Rafarma Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rafarma Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rafarma Pink Sheet. However, Rafarma Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.087 | Real 0.0693 | Hype 0.09 | Naive 0.0741 |
The real value of Rafarma Pink Sheet, also known as its intrinsic value, is the underlying worth of Rafarma Pharmaceuticals Company, which is reflected in its stock price. It is based on Rafarma Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Rafarma Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Rafarma Pharmaceuticals helps investors to forecast how Rafarma pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rafarma Pharmaceuticals more accurately as focusing exclusively on Rafarma Pharmaceuticals' fundamentals will not take into account other important factors: Rafarma Pharmaceuticals Total Value Analysis
Rafarma Pharmaceuticals is at this time forecasted to have valuation of 7.89 M with market capitalization of 110.29 M, debt of 292 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rafarma Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.89 M | 110.29 M | 292 K |
Rafarma Pharmaceuticals Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Rafarma suggests not a very effective usage of assets in December.Rafarma Pharmaceuticals Profitability Analysis
Net Loss for the year was (14.85 K) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Rafarma Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Rafarma Pharmaceuticals and how it compares across the competition.
About Rafarma Pharmaceuticals Valuation
The pink sheet valuation mechanism determines Rafarma Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Rafarma Pharmaceuticals. We calculate exposure to Rafarma Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rafarma Pharmaceuticals's related companies.Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Rafarma Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Rafarma Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Rafarma Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Rafarma Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Rafarma Pharmaceuticals' revenue streams: Identify Rafarma Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Rafarma Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Rafarma Pharmaceuticals' growth potential: Evaluate Rafarma Pharmaceuticals' management, business model, and growth potential.
- Determine Rafarma Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Rafarma Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Rafarma Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Retained Earnings | -2.4 M |
Complementary Tools for Rafarma Pink Sheet analysis
When running Rafarma Pharmaceuticals' price analysis, check to measure Rafarma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rafarma Pharmaceuticals is operating at the current time. Most of Rafarma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rafarma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rafarma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rafarma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |